Table 2. Characteristics of patients’ medication at baseline and at 12 months post surgery.

	Fang et al. (M0(%)/M12(%))		Sparks (M0(%)/M12(%))
	Surgery	Non surgery	Surgery	Non surgery
CSDMARDs	96.9/ 88.5	93.9/75.0	93/59**	-
Methotrexate	87.5 /59.4	81.8/71.4	-	-
Sulfasalazine	15.6/9.4	12.1/7.1	-	-
Leflunomide	56.3/ 19.2**	45.5/17.9*	-	-
Combination	65.6/28.1*	57.6 /28.6*	70/43*	-
Biological agents	43.8/15.6*	30.3/21.4	51/36**	-
Glucocrticoids	12.5/0	15.2/ 3.6	17/9*	-
NSAIDs	50.0/6.3**	51.5/25.0*	45/15*	-

*P < 0.05 and

**P < 0.01, csDMARDs: conventional disease-modifying anti-rheumatic drug, NSAIDs: non-steroidal anti-inflammatory drugs, M:months